TMDX TransMedics Group, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1756262 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY28.5%
TTM net income YoY57.4%
TTM EPS YoY48.0%
Revenue 3-yr CAGR56.0%
Net income 3-yr CAGR—
Margins
Gross margin58.6%
Operating margin11.9%
Net margin19.9%
FCF margin6.1%
EBITDA margin17.4%
Returns
ROE31.9%
ROA11.7%
ROIC (approx.)—
Asset turnover0.59x
Leverage & solvency
Liabilities / assets63.7%
Debt / equity0.00x
Current ratio4.53x
Interest coverage3.46x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio2.6%
Payout ratio—
Capex / revenue9.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $605.49M | $441.54M | $241.62M | $93.46M | $30.26M |
| Cost of revenue | $242.69M | $179.46M | $87.53M | $28.19M | $9.10M |
| Gross profit | $362.81M | $262.08M | $154.09M | $65.27M | $21.16M |
| R&D expense | $69.06M | $55.97M | $36.05M | $26.81M | $22.30M |
| SG&A expense | $185.17M | $168.62M | $119.55M | $69.90M | $38.28M |
| Operating income | $108.58M | $37.50M | -$28.73M | -$31.44M | -$39.43M |
| Interest expense | $13.78M | $14.41M | $10.79M | $3.73M | $3.87M |
| Pretax income | $107.52M | $35.78M | -$26.67M | -$36.16M | -$44.18M |
| Income tax | -$82.77M | $316,000 | -$1.64M | $66,000 | — |
| Net income | $190.29M | $35.46M | -$25.03M | -$36.23M | -$44.22M |
| EBITDA | $135.77M | $57.25M | -$20.55M | -$27.96M | -$37.61M |
| EPS (basic) | 5.60 | 1.07 | -0.77 | -1.23 | -1.60 |
| EPS (diluted) | 4.87 | 1.01 | -0.77 | -1.23 | -1.60 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 40.54M | 35.22M | 32.52M | 29.56M | 27.62M |
| Balance sheet | |||||
| Cash & equivalents | $488.87M | $337.15M | $395.31M | $201.68M | $26.08M |
| Short-term investments | — | — | — | — | $66.87M |
| Receivables | $84.28M | $97.72M | $63.58M | $27.61M | $5.93M |
| Inventory | $48.88M | $46.55M | $44.23M | $20.61M | $14.86M |
| Current assets | $637.78M | $497.22M | $510.65M | $252.29M | $118.70M |
| PP&E, net | $327.66M | $285.97M | $173.94M | $19.22M | $9.84M |
| Goodwill | $11.55M | $11.55M | $11.99M | — | — |
| Intangibles | $1.95M | $2.15M | $2.35M | — | — |
| Total assets | $1.07B | $804.08M | $706.05M | $277.15M | $134.89M |
| Current liabilities | $89.31M | $59.91M | $54.93M | $23.66M | $23.24M |
| Short-term debt | $10.00M | — | — | — | — |
| Long-term debt | — | — | — | $58.70M | $35.20M |
| Total debt | — | — | — | $58.70M | $35.20M |
| Total liabilities | $595.27M | $575.47M | $568.85M | $89.77M | $67.04M |
| Shareholders' equity | $473.10M | $228.60M | $137.20M | $187.38M | $67.85M |
| Net debt | — | — | — | -$142.99M | $9.12M |
| Shares outstanding | 34.27M | 33.62M | 32.67M | 32.14M | 27.79M |
| Cash flow statement | |||||
| Operating cash flow | $192.84M | $48.80M | -$13.03M | -$45.82M | -$28.86M |
| Capital expenditure | $59.25M | $129.74M | $151.85M | $11.91M | $3.52M |
| Free cash flow | $133.59M | -$80.94M | -$164.88M | -$57.72M | -$32.38M |
| Investing cash flow | -$59.25M | -$129.30M | -$193.95M | $54.51M | $29.27M |
| Financing cash flow | $16.86M | $22.87M | $400.42M | $167.93M | $1.39M |
| Depreciation & amortization | $27.18M | $19.76M | $8.18M | $3.48M | $1.82M |
| Stock-based compensation | $36.86M | $33.22M | $19.79M | $10.32M | $6.88M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.